The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.
Andrew David Seidman
Research Funding - Genta
Lee Steven Schwartzberg
Consultant or Advisory Role - Genta
Joyce O'Shaughnessy
No relevant relationships to disclose
Gabriella D'Andrea
No relevant relationships to disclose
Peter Rubin
No relevant relationships to disclose
Seth Katz
No relevant relationships to disclose
Hassan Danesi
Employment or Leadership Position - Genta
Loretta Itri
Employment or Leadership Position - Genta (I); Genta
Stock Ownership - Genta (B)
Clifford Hudis
No relevant relationships to disclose